FI963028A - RZR-reseptoriperheen avulla suoritettava seulontamenetelmä - Google Patents

RZR-reseptoriperheen avulla suoritettava seulontamenetelmä Download PDF

Info

Publication number
FI963028A
FI963028A FI963028A FI963028A FI963028A FI 963028 A FI963028 A FI 963028A FI 963028 A FI963028 A FI 963028A FI 963028 A FI963028 A FI 963028A FI 963028 A FI963028 A FI 963028A
Authority
FI
Finland
Prior art keywords
rzr
method performed
screening method
receptor family
receptor
Prior art date
Application number
FI963028A
Other languages
English (en)
Swedish (sv)
Other versions
FI963028A0 (fi
Inventor
Irmgard Wiesenberg
Martin Missbach
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI963028A0 publication Critical patent/FI963028A0/fi
Publication of FI963028A publication Critical patent/FI963028A/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
FI963028A 1994-03-30 1996-07-31 RZR-reseptoriperheen avulla suoritettava seulontamenetelmä FI963028A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810196 1994-03-30
PCT/EP1995/001017 WO1995027202A1 (en) 1994-03-30 1995-03-18 Screening method using the rzr receptor family

Publications (2)

Publication Number Publication Date
FI963028A0 FI963028A0 (fi) 1996-07-31
FI963028A true FI963028A (fi) 1996-09-27

Family

ID=8218235

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963028A FI963028A (fi) 1994-03-30 1996-07-31 RZR-reseptoriperheen avulla suoritettava seulontamenetelmä

Country Status (8)

Country Link
US (2) US5958683A (fi)
EP (1) EP0753147A1 (fi)
JP (1) JPH09511334A (fi)
AU (1) AU2109695A (fi)
CA (1) CA2182700A1 (fi)
FI (1) FI963028A (fi)
HU (1) HUT75128A (fi)
WO (1) WO1995027202A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746313B1 (fr) * 1996-03-22 1998-04-17 Adir Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
FR2776388B1 (fr) * 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
ATE234084T1 (de) 1998-06-02 2003-03-15 Arthromics Plc Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
GB9924057D0 (en) * 1999-10-11 1999-12-15 Novartis Ag Organic compounds
FR2813315B1 (fr) * 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
AU2003227689A1 (en) * 2002-04-29 2003-11-17 Novartis Ag Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
WO2004047855A2 (en) * 2002-11-27 2004-06-10 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis
WO2004052302A2 (en) * 2002-12-10 2004-06-24 The Regents Of The University Of California A method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2005037324A1 (en) * 2003-10-16 2005-04-28 Irm Llc Methods and compositions for modulating circadian rhythm
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH459216A (de) * 1965-10-29 1968-07-15 Geigy Ag J R Verfahren zur Herstellung von neuen Azinen
CH511877A (de) * 1969-07-17 1971-08-31 Ciba Geigy Ag Verfahren zur Herstellung eines neuen Thiosemicarbazons
DE2632747A1 (de) * 1975-08-06 1977-02-24 Ciba Geigy Ag Azine von sechs- und siebengliedrigen thiazaheterocyclen
EP0085275B1 (de) * 1982-01-22 1986-02-19 Ciba-Geigy Ag Substituierte Thiazolidinylester von Mineralsäuren
US4771056A (en) * 1985-08-29 1988-09-13 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US6492137B1 (en) * 1989-11-16 2002-12-10 The Salk Institute For Biological Studies Response element compositions and assays employing same
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69115221T2 (de) * 1990-09-28 1996-08-22 I F L O S A S Di Giorgio E Ald Methode zur Synthese eines Präparats zur Regulation der Empfängnis und des Menstruationszyklus mit onkostatischen antikinetosischen, preventiven und therapeutischen Eigenschaften zur Behandlung von Brustkrebs und Melanomen.
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
AU679899B2 (en) * 1991-03-18 1997-07-17 Salk Institute For Biological Studies, The Response element compositions and assays employing same
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU658175B2 (en) * 1991-04-12 1995-04-06 Novartis Ag Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0548017A1 (de) * 1991-12-18 1993-06-23 Ciba-Geigy Ag Neue Thiazole
TW211005B (fi) * 1991-12-18 1993-08-11 Ciba Geigy Ag
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0565296B1 (en) * 1992-04-07 1996-08-07 Neurim Pharmaceuticals (1991) Limited Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds

Also Published As

Publication number Publication date
CA2182700A1 (en) 1995-10-12
HU9602670D0 (en) 1996-11-28
FI963028A0 (fi) 1996-07-31
AU2109695A (en) 1995-10-23
JPH09511334A (ja) 1997-11-11
WO1995027202A1 (en) 1995-10-12
EP0753147A1 (en) 1997-01-15
US6218359B1 (en) 2001-04-17
MX9603966A (es) 1997-12-31
HUT75128A (en) 1997-04-28
US5958683A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
FI972318A0 (fi) Menetelmä ikkunan irrottamiseksi
DE69421128D1 (de) Siebmaschine
DE59708166D1 (de) Röntgenaufnahme-Verfahren
NO944290D0 (no) Fremgangsmåte for undersökelse av et brönnhull
NO944289D0 (no) Fremgangsmåte for undersökelse av et brönnhull
DE69523119T2 (de) Bilderzeugungsverfahren
FI963571A0 (fi) Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
NO974437L (no) Fremgangsmåte for screening av forbindelsen for östrogenaktivitet
FI963028A (fi) RZR-reseptoriperheen avulla suoritettava seulontamenetelmä
DE69526199T2 (de) Bilderzeugungsverfahren
FI971485A0 (fi) Sits
DE69535174D1 (de) Bilderzeugungsverfahren
DE69620071D1 (de) Siebvorrichtung
BR9605700A (pt) Máquina de peneiraçao
DE69511125D1 (de) Bildherstellungsverfahren
BR9510060A (pt) Receptor
ATA29894A (de) Siebwehr (grundwehr)
DE29504773U1 (de) Trommel
FI942585A0 (fi) Menetelmä kaapelin jatkamiseksi
NO950029D0 (no) Festeelement og fremgangsmåte for fremstilling av samme
SE9403395D0 (sv) Silanordning
DE29522022U1 (de) Siebmaschine
UA24714A (uk) Просіювач
DE9414163U1 (de) Rüttelsiebeinsatz
NO943350D0 (no) Anordning for sikting av flis

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG